Full-Time

Senior Director/ Director Regulatory Strategy

Updated on 9/3/2026

Vor Bio

Vor Bio

51-200 employees

Develops targeted therapies for blood cancers

Compensation Overview

$210k - $285k/yr

Boston, MA, USA

Remote

Remote role; occasional travel for regulatory meetings.

Bachelor's, Master's, PharmD, PhD, MD

Category
Biology & Biotech (1)

Get referred to Vor Bio

See people who can refer or advise you

Requirements
  • Bachelor’s degree required; Relevant advanced degree preferred (PhD, PharmD, MD, MSc, or equivalent in life sciences).
  • 7+ years of progressively responsible experience in Regulatory Affairs within the pharmaceutical industry.
  • Demonstrated experience leading global regulatory strategies for development programs and/or major regulatory submissions.
  • Proven success in direct interactions with global regulatory authorities.
  • Experience working in matrixed, cross-functional development teams.
  • Remote role; occasional travel required for regulatory meetings and internal governance forums.
  • Strong strategic thinking with the ability to balance regulatory risk, scientific evidence, and business objectives.
  • Deep understanding of global regulatory frameworks and product development.
  • Excellent leadership, influence, and communication skills, including the ability to engage senior executives.
  • Ability to navigate ambiguity and drive alignment across diverse stakeholders.
  • Strong written and verbal communication skills.
Responsibilities
  • Develop and lead global, integrated regulatory strategies for investigational and marketed products across the product lifecycle, including late stage development.
  • Provide strategic input on development plans, target product profiles, labeling, indications, and sequencing of regulatory submissions.
  • Anticipate and mitigate regulatory risks; proactively identify opportunities for regulatory flexibility, expedited programs, and innovative pathways.
  • Serve as a key regulatory advisor to senior leadership and cross-functional governance bodies.
  • Lead and/or oversee global regulatory authority interactions, including IND/CTA meetings, End-of-Phase meetings, scientific advice, and other milestone interactions.
  • Develop briefing documents, talking points, and negotiation strategies aligned with program objectives.
  • Interpret and communicate regulatory feedback to cross-functional teams and translate it into actionable plans.
  • Provide strategic oversight for major regulatory filings (e.g., INDs/CTAs, NDAs/BLAs/MAAs, supplements, variations).
  • Ensure submission strategies are aligned with global regulatory expectations and business priorities.
  • Review and approve regulatory strategy documents, submission plans, and key content from a strategic perspective.
  • Partner closely with Clinical Development, Biostatistics, CMC, Nonclinical, Pharmacovigilance, Quality, and Commercial teams to align regulatory strategy with development and commercialization goals.
  • Influence program decision-making by integrating regulatory considerations early and consistently.
  • Support due diligence, licensing, and business development activities from a regulatory standpoint.
  • Mentor and develop regulatory strategists and/or regulatory leads; provide strategic oversight within a matrixed team environment.
  • Contribute to the evolution of regulatory strategy capabilities, processes, and best practices within the organization.
  • Promote a culture of scientific rigor, regulatory excellence, and proactive risk management.
  • Monitor and interpret evolving global regulatory trends, guidance, and policy changes relevant to assigned programs or therapeutic areas.
  • Assess the impact of regulatory intelligence on development and lifecycle strategy.
Desired Qualifications
  • Experience in a specific therapeutic area is a plus (e.g.,rare disease, immunology, neurology).
  • Experience with accelerated pathways (e.g., Fast Track, Breakthrough Therapy).
  • Experience supporting global commercialization and post-approval lifecycle activities.

Vor Biopharma focuses on developing therapies for blood cancers, especially AML, with a platform designed to protect healthy cells while targeting cancer cells. Its product approach centers on research and development of a proprietary treatment platform and a pipeline of therapies, funded through partnerships, licensing deals, and eventual commercialization after regulatory approval. The company differentiates itself by its emphasis on selectively sparing healthy cells, a collaborative cross-functional team led by experienced biopharma leaders (including founder Dr. Siddhartha Mukherjee), and a business model built on collaborations rather than solely internal sales. The goal is to transform blood cancer treatment by delivering therapies that minimize collateral damage to healthy tissue and bring effective treatments to patients through R&D, partnerships, and eventual market commercialization.

Company Size

51-200

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2015

Get referred to Vor Bio

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • June 8, 2026 SjD approval in China de-risks the biology.
  • March 30, 2026 UPSTREAM SjD dosing starts global registrational execution.
  • $514.5 million cash funds operations into early 2029, financing both Phase 3 trials.

What critics are saying

  • UPSTREAM MG topline slips beyond 1H27, delaying U.S. filings and commercialization.
  • Roche, UCB, and argenx crowd gMG; differentiation must beat entrenched biologics.
  • If telitacicept misses Western trials, Vor Bio becomes a cash-burning licensing shell.

What makes Vor Bio unique

  • Telitacicept blocks BAFF and APRIL, unlike single-target autoimmune drugs.
  • China approvals in 2023-2026 validate telitacicept across five indications.
  • Vor Bio now focuses on gMG and SjD global Phase 3 programs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Paid Vacation

Parental Leave

401(k) Retirement Plan

401(k) Company Match

Commuter Benefits

Growth & Insights and Company News

Headcount

6 month growth

-6%

1 year growth

-19%

2 year growth

-11%
Market Wire News
Sep 1st, 2026
Vor Bio to participate in upcoming September conferences.

Vor Bio to participate in upcoming September conferences. MWN-AI** Summary. Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to innovating treatments for autoimmune diseases, has announced its participation in several upcoming investor conferences throughout September 2026. The company's management aims to engage with investors and stakeholders through various formats, including fireside chats and one-on-one meetings. The schedule kicks off with the Wells Fargo 21st Annual Healthcare Conference on September 8, where Vor Bio will provide insights during a fireside chat set for 8:00 AM ET. Following that, on September 9, the company will take part in Citi's 2026 Biopharma Back to School Conference, occurring at 11:20 AM ET, again featuring a fireside chat and individual meetings. Subsequent appearances include participation in Morgan Stanley's 24th Annual Global Healthcare Conference on September 14, focused on one-on-one discussions, and the Baird 2026 Global Healthcare Conference on September 15 with a scheduled presentation at 9:05 AM ET, alongside additional meetings. Concluding this conference series, Vor Bio will present at Stifel's 2026 Virtual Immunology and Inflammation Forum on September 23 at 11:30 AM ET. Investors interested in following the discussions can access live webcasts of these presentations via the Investors section of Vor Bio's website, where replays will also be available for roughly 30 days post-event. Vor Bio is progressing its lead candidate, telitacicept - a novel dual-target fusion protein advancing through Phase 3 clinical development - aimed at addressing serious autoantibody-driven conditions globally. For further details, investors are encouraged to visit Vor Bio's website at www.vorbio.com and stay updated through the company's dedicated investor communications. MWN-AI** Analysis. Vor Bio (Nasdaq: VOR) is gearing up to participate in several prominent investor conferences this September, and this could present significant opportunities for investors to glean insights into the company's strategic direction and clinical ambitions. The market hopes to keep an eye on the presentations scheduled at conferences hosted by Wells Fargo, Citi, Morgan Stanley, Baird, and Stifel. Vor Bio is actively advancing its lead program, telitacicept, aimed at addressing critical autoimmune diseases. Robust engagement during these conferences could help elevate investor confidence, particularly as the company progresses through Phase 3 clinical trials. Investors should focus on the messaging from management during the upcoming fireside chats and presentations. Specifically, look for updates on telitacicept's clinical trial results, patient enrollment rates, and timelines toward regulatory submissions and potential commercialization. Strong clinical data announcements or proactive management during these discussions could act as price catalysts for the stock. As September is often a month filled with economic announcements and market volatility, Vor Bio's strategic participation may provide more than just clinical insights; it could serve as a bellwether for investor sentiment in the biotech sector. Given that the market tends to react positively to transparency and proactive engagement from clinical-stage companies, an effective showcasing of telitacicept's potential could foster upward momentum for VOR shares. Investors should also monitor how Vor Bio navigates questions regarding competition and market dynamics in the autoimmune treatment landscape. These insights are vital as they may address investor concerns around differentiation and market positioning. In summary, the upcoming conferences are a crucial juncture for Vor Bio, representing an opportunity for strong engagement with the investment community. Cautious investors may consider positioning themselves ahead of these events while keeping a close watch on developments. **MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release. September 01, 2026 08:00:00 am BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) - Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that management will participate in the following investor conferences: * Wells Fargo 21st Annual Healthcare Conference Forum: Fireside Chat and 1x1 Meetings Date: Tuesday, September 8th Presentation Time: 8:00AM ET * Citi's 2026 Biopharma Back to School Conference Forum: Fireside Chat and 1x1 Meetings Date: Wednesday, September 9th Presentation Time: 11:20AM ET * Morgan Stanley 24th Annual Global Healthcare Conference Forum: 1x1 Meetings Date: Monday, September 14th * Baird's 2026 Global Healthcare Conference Forum: Presentation and 1x1 Meetings Date: Tuesday, September 15th Presentation Time: 9:05AM ET * Stifel's 2026 Virtual Immunology and Inflammation Forum Forum: Presentation and 1x1 Meetings Date: Wednesday, September 23rd Presentation Time: 11:30AM ET A live webcast of the presentation may be accessed on the Investors section of the Vor website at ir.vorbio.com. A replay of the webcast will be available on the Vor website for approximately 30 days following the presentation. About Vor Bio Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com. Vor Bio routinely posts information that may be important to investors in the "Investors" section of its website. The Company encourages investors to consult that section of its website regularly. Media & Investor Contacts:Carl [email protected] FAQ**. How does Vor Biopharma Inc. VOR plan to differentiate its dual-target fusion protein, telitacicept, from existing treatments for autoimmune diseases presented at the upcoming investor conferences? Vor Biopharma Inc. plans to differentiate telitacicept by showcasing its dual-target mechanism that potentially offers enhanced efficacy and safety over existing treatments for autoimmune diseases during the upcoming investor conferences. What specific data or progress regarding telitacicept will Vor Biopharma Inc. VOR share during the Wells Fargo and Citi conferences that could impact investor sentiment? Vor Biopharma Inc. is expected to share updated clinical trial results and potential partnerships for telitacicept during the Wells Fargo and Citi conferences, which could significantly impact investor sentiment towards the drug's efficacy and market potential. Can you elaborate on Vor Biopharma Inc. VOR's timeline for Phase 3 clinical development and what milestones will be highlighted during the investor presentations? As of now, Vor Biopharma Inc. is expected to provide updates on its Phase 3 clinical development timeline and key milestones at upcoming investor presentations, focusing on the advancements of its lead candidate and the anticipated enrollment of patients in 2026. How does Vor Biopharma Inc. VOR intend to leverage feedback from investors at the upcoming conferences to shape its commercialization strategies for telitacicept? Vor Biopharma Inc. plans to gather investor insights at upcoming conferences to refine its commercialization strategies for telitacicept, focusing on market needs and feedback to enhance product positioning and stakeholder engagement. **MWN-AI FAQ is based on asking OpenAI questions about Vor Biopharma Inc. (NASDAQ: VOR).

Associated Press
Aug 11th, 2026
Vor Bio reports $514.5M cash balance, expects runway into early 2029

Vor Bio reported second quarter 2026 financial results and provided updates on its clinical programmes for telitacicept, a dual BAFF/APRIL inhibitor for autoimmune diseases. The company reported a cash position of $466.1 million as of 30 June 2026. Combined with $48.4 million in net proceeds from July 2026 at-the-market sales, the pro-forma balance of $514.5 million is projected to fund operations into early 2029. Enrollment continues for the Phase 3 UPSTREAM MG trial in generalised myasthenia gravis, with topline results anticipated in the first half of 2027. Enrollment is also ongoing for the Phase 3 UPSTREAM SjD trial in primary Sjögren's disease. Telitacicept has received commercial approvals in China for treating Sjögren's disease and IgA nephropathy, bringing its total to five approved indications in the country.

Vor Bio
Jul 7th, 2026
Vor Bio appoints David Zaccardelli to Board of Directors.

Vor Bio appoints David Zaccardelli to Board of Directors. July 7, 2026 BOSTON, July 07, 2026 (GLOBE NEWSWIRE) - Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David Zaccardelli, Pharm.D., to its Board of Directors. With more than 20 years of biopharmaceutical leadership experience, Dr. Zaccardelli has successfully built and led companies through late-stage development, regulatory approval, and commercial launch. "We are excited to welcome David to the Board of Directors at an important stage in the company's evolution," said Jean-Paul Kress, M.D., Chairman and Chief Executive Officer of Vor Bio. "David is a proven biotech operator with a distinguished track record of leading companies through periods of significant growth, from late-stage development to commercial execution. His experience building organizations, launching medicines, and creating shareholder value will be invaluable as we advance telitacicept through global Phase 3 development and build a leading immunology company." Dr. Zaccardelli served as President, Chief Executive Officer, and on the board of directors of Verona Pharma from February 2020 until its acquisition by Merck for $10 billion in October 2025. During his tenure, Verona advanced from a clinical-stage company to a commercial-stage organization, successfully completing two Phase 3 trials, receiving FDA approval, and launching Ohtuvayre(R) for chronic obstructive pulmonary disease. Under his leadership, Verona raised more than $1 billion to support development and commercialization and became one of the top-performing biotechnology companies on Nasdaq in 2024 based on its five-year increase in market value. Dr. Zaccardelli was recognized as Executive of the Year at the 2023 Scrip Awards. Currently, he serves as Chair of the Board of Directors for SAB BIO and Founder and Managing Member of Bull City Select Investments, LLC. Prior to Verona, Dr. Zaccardelli served as President and Chief Executive Officer of Dova Pharmaceuticals, a rare disease company acquired by Swedish Orphan Biovitrum in 2019 for up to $915 million. He previously served as Acting Chief Executive Officer of Cempra through its merger with Melinta Therapeutics and held several senior leadership roles at United Therapeutics Corporation, including Chief Operating Officer, Chief Manufacturing Officer and Executive Vice President, Pharmaceutical Development and Operations. Earlier in his career, Dr. Zaccardelli founded and led a contract research start-up and held clinical research roles at Burroughs Wellcome, Glaxo Wellcome and Bausch & Lomb Pharmaceutical. He received a Pharm.D. from the University of Michigan and completed a fellowship in clinical research and drug development at the University of North Carolina. "Vor is at an exciting inflection point," said Dr. Zaccardelli. "Telitacicept has the potential to become an important therapy across multiple autoimmune diseases, and Vor has the team, capital and urgency to execute. I look forward to working with Jean-Paul, the Board, and the management team as the company advances telitacicept and enters its next phase of growth." In connection with Dr. Zaccardelli's appointment, Andrew Levin, M.D., Ph.D., an Advisor at RA Capital Management, has stepped down from Vor Bio's Board of Directors. "On behalf of the Board and management team, I want to thank Andrew for his leadership, counsel and commitment to Vor," said Dr. Kress. "Andrew has been an instrumental partner during a pivotal period of transformation for the company and we are grateful for his many contributions." About Telitacicept Telitacicept is a novel recombinant fusion protein designed to treat autoimmune diseases through dual inhibition of BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), generalized myasthenia gravis (gMG), IgA nephropathy (IgAN), and Sjögren's disease (SjD). Vor Bio is advancing telitacicept in global Phase 3 trials in gMG and SjD to support potential regulatory approvals in the United States, Europe, and Japan. About Vor Bio Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com. Vor Bio routinely posts information that may be important to investors in the "Investors" section of its website. The Company encourages investors to consult that section of its website regularly. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "continue," "could," "design," "expect," "intend," "may," "ongoing," "plan," "potential," "should," "update," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio's statements regarding telitacicept's potential to become an important therapy across multiple autoimmune diseases; Vor Bio's development and commercialization plans for telitacicept; Vor Bio's board of directors' transition; and other statements that are not historical fact. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including that the data for its product candidates may not be sufficient for obtaining regulatory approval to commercialize products; Vor Bio, Inc. may not be able to execute its business plans, including meeting its planned clinical and regulatory milestones and timelines, and possible limitations of financial and other resources. These and other risks are described in greater detail under the caption "Risk Factors" included in Vor Bio's most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law. Media & Investor Contacts: Carl Mauch [email protected]

Associated Press
May 13th, 2026
Vor Bio reports $491.5M cash balance, gMG trial results expected in 1H27

Vor Bio, a clinical-stage biotechnology company, reported first quarter 2026 financial results and announced its cash position of $491.5 million is expected to fund operations into early 2029. The company is advancing two Phase 3 trials of telitacicept, a dual BAFF/APRIL inhibitor. The UPSTREAM MG trial in generalised myasthenia gravis is on track with topline results anticipated in the first half of 2027, whilst enrollment continues for the UPSTREAM SjD trial in primary Sjögren's disease. Research and development expenses decreased to $17.6 million from $26.7 million year-over-year, primarily due to reduced spending on previous programmes. The company reported a net loss of $219.6 million for the quarter, compared to $32.5 million in the same period last year, mainly due to changes in fair value of outstanding liability-classified warrants.

Microsoft
Mar 27th, 2026
Vor Bio announces $75M private placement

Vor Bio (VOR) said on Friday it had entered a securities purchase agreement to sell 5.34M shares at $14.05 each in a private placement, for gross proceeds of about $75M. The private placement is expected to close on or about March 30, 2026. The financing is led by new investor TCGX. The net proceeds from the offering will be used for advancing teli...